Previous close | 68.26 |
Open | 68.18 |
Bid | 67.95 x 600 |
Ask | 68.05 x 700 |
Day's range | 67.93 - 68.35 |
52-week range | 60.47 - 76.56 |
Volume | |
Avg. volume | 6,330,690 |
Market cap | 210.812B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 35.79 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.45 (2.12%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
WILMINGTON, Del., March 25, 2024--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1
WILMINGTON, Del., March 19, 2024--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
WILMINGTON, Del., March 18, 2024--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease (COPD), including those who are uninsured and underinsured.